EMEA Suspends Hexavac Marketing Authorization
This article was originally published in The Pink Sheet Daily
Executive Summary
Decreased immunogenicity of Sanofi-Pasteur/Merck’s hepatitis B component appears to have been caused by “variability in the production process.”
You may also be interested in...
Sanofi-Pasteur Gets $100 Mil. HHS Contract to Make Avian Influenza Vaccine
The number of viable doses will depend upon the outcome of ongoing dosing studies, HHS says.
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency